We serve Chemical Name:2-Methyl-2-propanyl 3-formylbenzoate CAS:247186-56-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Methyl-2-propanyl 3-formylbenzoate
CAS.NO:247186-56-7
Synonyms:2-Methyl-2-propanyl 3-formylbenzoate;Benzoic acid, 3-formyl-, 1,1-dimethylethyl ester
Molecular Formula:C12H14O3
Molecular Weight:206.238
HS Code:2918300090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:304.6±25.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.534
PSA:43.37000
Exact Mass:206.094299
LogP:3.13
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-Methyl-2-propanyl 3-formylbenzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzoic acid, 3-formyl-, 1,1-dimethylethyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzoic acid, 3-formyl-, 1,1-dimethylethyl ester Use and application,Benzoic acid, 3-formyl-, 1,1-dimethylethyl ester technical grade,usp/ep/jp grade.
Related News: The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. 2-Methyl-2-propanyl 3-formylbenzoate manufacturer The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. 2-Methyl-2-propanyl 3-formylbenzoate supplier There are also new directives that relate to US citizens. 2-Methyl-2-propanyl 3-formylbenzoate vendor Compared with individuals with cancer only, those with ASCVD and with ASCVD and cancer had a significantly higher presence of three of more of these factors (23 and 30 percent, respectively, versus 13 percent). 2-Methyl-2-propanyl 3-formylbenzoate factory In a memo to Branchburg employees on May 20, Nellie Clark, head of the plant, summed up the outside lawyers’ findings: “In the end and very importantly, allegations that Lilly made false statements to the FDA were not substantiated.”
